Health-Related Research

Chemical Constituents of Noni (Morinda citrifolia)
Following is a partial list of chemical constituents isolated from
noni, and their proposed or documented medicinal qualities or cultural
significance. The table was assembled from the literature presented in
the "Noni Bibliography" on this web site. There are reportedly
numerous other compounds isolated from the noni plant that may have
significant biological activity and are currently under investigation.
Noni Plant organ(s) Compound(s) Proposed or documented effects of
compounds Discussion & Notes
FRUIT and FRUIT JUICE Alkaloids (xeronine) In theory, xeronine enhances
enzyme activity and protein structure *According to some authorities,
the existence and the proposed effects of the so-called alkaloid,
xeronine, and/or the compound, pre-xeronine, have not been
substantiated.
 Polysaccharides (glucuronic acid; galactose; arabinose; rhamose;
glycosides; trisaccharide fatty acid ester) Immuno-stimulatory;
immuno-modulatory; anti-bacterial; anti-tumor; anti-cancer. A promising
area for research and a highly beneficial set of compounds.
 Scopoletin Dilates vasculature & lowers blood pressure;
anti-bacterial & anti-fungal; anti-inflammatory; analgesic;
histamine-inhibiting; arthritic conditions; allergies; sleep disorders;
migraine headaches; depression; Alzheimer's disease. Potentially wide
applications.
 Vitamins and Minerals: magnesium; iron; potassium; selenium; zinc;
copper; sulfur; ascorbic acid (vitamin C). The positive medical effects
of the vitamins and minerals in noni juice are well documented. For any
questions or medical and health concerns, consult a physician or
dietician. Noni juice is an excellent source of vitamin C.
FOLIAGE & CELL SUSPENSIONS Anthraquinones (damnacanthal) Antiseptic &
antibacterial effects in digestive tract (Staphylococcus, Shingela,
Salmonella). Internal application.
 Glycosides (flavonol glycoside; iridoid glycoside,
"citrifolinoside") Anti-cancer effects: (DPPH free radical
scavenging activity; inhibition of UVB-induced Activator Protein-1
activity in cell cultures. Discovery reported in 2001.
ROOTS Anthraquinones (damnacanthal) Inhibits formation of lung
carcinoma in mice. Research from University of Hawai'i at Manoa
 Morindin and Morindone Dyes, yellow and red colorants used for tapa
cloth; anti-bacterial. Culturally significant.

It's not that the rate of cancer has anything to do with filth.  "It's
the fruit"  -- by your undeveloped view.

What a joke.

On June 7, Steve Kramer replied to that which calls itself "Leah" and
writes (June 4) that "..aggressive treatment of cancer is never a good
idea.":

Quoting "Leah":

Steve K wrote:

Hee hee, pretty much a quote from the novel _True Grit_ by Charles
Portis and the Duke Wayne movie based upon it. The movie is one of the
few I've seen that closely follow not only the plotline but the dialogue
of the movie. This is a quote of Mattie Ross from both.

Well done, Steve K.

Regards,

Steve J

"I am under no obligation to respect your beliefs. Respect is earned; it
is not an entitlement..."
-- Lionel Shriver

Yawn.

Camels, like I said.

On August 26, 1998, the Attorneys General of Arizona, California, New
Jersey, and Texas announced a multi-state settlement with Morinda, Inc., a
multilevel company headquartered in Linden, Utah. The states had charged
that Morinda had made unsubstantiated claims in consumer testimonials and
other promotional material that its "Tahitian Noni" juice could treat, cure
or prevent numerous diseases, including diabetes, depression, hemorrhoids
and arthritis. Such claims rendered the beverage an unapproved new drug
under state and federal food and drug laws and should not have been sold
until it received approval. Under the terms of the agreement, Morinda must:

 a.. No longer make drug claims, or claims that the product can cure,
treat, or prevent any disease until "Tahitian Noni" is approved and cleared
for those uses by the U.S. Food and Drug Adminstration.
 b.. Not make any other claims, whether health claims or others, regarding
the benefits of "Tahitian Noni" unless such claims are true and the company
can substantiate the claim by reliable scientific evidence.
 c.. Not use testimonials which imply that the advertised claimed results
are the typical or ordinary experience of consumers in actual conditions of
use, unless Morinda possesses and relies upon adequate substantiation that
the results are typical or ordinary.
In addition, Morinda must refund to any consumer who requests a refund in
writing, the full purchase price paid for the product. The agreement also
calls for Morinda to pay $100,000 for investigative costs.

May 6, 2002

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

Noni Juice Sales
Post Office Box 55
West Barnstable, Massachusetts 02668

Ref. No. CL-02-HFS-810-15

Dear Sir or Madam:

This is to advise you that the Food and Drug Administration (FDA) has
reviewed your web site at the Internet address: http://www.4-nonijuice.com 
and has determined that the product "Noni Juice" being offered is promoted
for conditions that cause the product to be a drug under section 201(g)(1)
of the Federal Food, Drug, and Cosmetic Act (the Act) [21 USC 321(g)(1)].
The therapeutic claims on your web site establish that the product is a drug
because it is intended for use in the cure, mitigation, treatment, or
prevention of disease. The continued marketing of this product with these
claims violates the Act and may subject you or the product to regulatory
action without further notice.

Examples of some of the claims observed on your web site include:

 "Primary benefits of Noni Juice include: helps lower high blood
pressure $B!D(B acts as anti-inflammatory and anti-histaminic agent, alleviates
pain, can help protect against digestive problems, inhibits precancer
function and growth of cancer tumors!"

 "After 3 weeks of being on the Noni Juice, I find that my heart is beating
normally, my cholesterol level is in the normal range, arthritis in my right
foot is gone, I am no longer impotent (a ten-year side-effect of the heart
medications)."

Furthermore, FDA has no information that your product is generally
recognized as safe and effective for the above referenced conditions and
therefore, the product may also be a "new drug" under section 201 (p) of the
Act [21 USC 321(p)]. New drugs may not be legally marketed in the U.S.
without prior approval from FDA as described in section 505 (a) of the Act
[21 USC 355(a)]. FDA approves a new drug on the basis of scientific data
submitted by a drug sponsor to demonstrate that the drug is safe and
effective.

FDA is aware that Internet distributors may not know that the products they
offer are regulated as drugs or that these drugs are not in compliance with
the law. Many of these products may be legally marketed as dietary
supplements or as cosmetics if therapeutic claims are removed from the
promotional materials and the products otherwise comply with all applicable
provisions of the Act and FDA regulations.

Under the Act, as amended by the Dietary Supplement Health and Education Act
(DSHEA), dietary supplements may be legally marketed with truthful and
non-misleading claims to affect the structure or function of the body
(structure/function claims), if certain conditions are met. However, claims
that dietary supplements are intended to prevent, diagnose, mitigate, treat,
or cure disease (disease claims), excepting health claims authorized for use
by FDA, cause the products to be drugs. The intended use of a product may be
established through product labels and labeling, catalogs, brochures, audio
and videotapes, Internet sites, or other circumstances surrounding the
distribution of the product. FDA has published a final rule intended to
clarify the distinction between structure/function claims and disease
claims. This document is available on the Internet at
http://vm.cfsan.fda.gov/~lrd/fr000106.html (codified at 21 C.F.R.
101.93(g)).

In addition, only products that are intended for ingestion may be lawfully
marketed as dietary supplements. Topical products and products intended to
enter into the body directly through the skin or mucosal tissues, such as
transdermal or sublingual products, are not dietary supplements. For these
products, both disease and structure/function claims may cause them to be
new drugs.

Certain over-the-counter drugs are not new drugs and may be legally marketed
without prior approval from FDA. Additional information is available in
Title 21 of the Code of Federal Regulations (21 CFR) Parts 310 and 330-358,
which contain FDA's regulations on over-the-counter drugs.

This letter is not intended to be an all-inclusive review of your web site
and products your firm may market. It is your responsibility to ensure that
all products marketed by your firm are in compliance with the Act and its
implementing regulations.

If you need additional information or have questions concerning any products
distributed through your web site, please contact FDA. You may reach FDA
electronically (e-mail) at APaeng@CFSAN.FDA.GOV, or you may respond in
writing to Andrew H. Paeng, Compliance Officer, Food and Drug
Administration, Division of Compliance and Enforcement, ONPLDS, 5100 Paint
Branch Parkway, College Park, Maryland 20740-3835. If you have any questions
concerning any issue in this letter, please contact Mr. Paeng at (301)
436-2375.

Sincerely yours,

/s/

John B. Foret Director
Division of Compliance and Enforcement
Office of Nutritional Products, Labeling and Dietary Supplements
Center for Food Safety and Applied Nutrition

And I haven't fired the broadside yet........

Keep defending sweetheart........